Read + Share
Liang Y, Maeda O, Kondo C, Nishida K, et al. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of
immune checkpoint inhibitors among patients with lung adenocarcinoma. PLoS One 2024;19:e0307580.
PMID: 39037971
|
 |
|
Liang Y, Maeda O, Kondo C, Nishida K, et al. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of
immune checkpoint inhibitors among patients with lung adenocarcinoma. PLoS One 2024;19:e0307580.
PMID: 39037971
|
|
|
|